Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

Investor Relations

Change
Volume
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.

Events
News Releases
January 13, 2020
electroCore Provides Business Update and Select Financial Guidance
BASKING RIDGE, N.J. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on its commercial operations, clinical development programs, and introduced select preliminary unaudited guidance for the fourth
December 27, 2019
electroCore Announces Board of Directors Transition
BASKING RIDGE, N.J. , Dec. 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox , will resign from the Board effective March 31, 2020 . Ms.

Investor Contact

Investor Relations

Hans Vitzthum, LifeSci Advisors
investors@electrocore.com